Evaluation of the effect of melatonin in patients with Burning mouth syndrome: a double-blind, placebo-controlled randomized clinical trial

Abstract The present study was carried out to evaluate the effect of Melatonin and Placebo in the patient with the Burning mouth (BMs). This double-blind, placebo-controlled randomized clinical trial study was carried out on 30 patients who were suffering from BMS. During this period patients were divided into 2 study and control groups. The study group used four 3 mg Melatonin daily and the control group received a placebo. Then the severity of the burning sensation was measured by the physician Sleep quality was measured using the VAS scale using the Petersburg questionnaire. Data in the application Enter SPSS 20 and then using T test or equivalent Nonparametric was analyzed, mean sleep score and mean severity of oral irritation before and after treatment in two the group was evaluated using T-test Independent. Level significance was considered 0.05. The results of the present study show that the use of melatonin and a placebo in patients with BMS reduces sensation and improves their sleep quality, although it may not reduce it completely. In this study severity of burning was 4.93±2.56 after treatment in the study group and 6.93±2.12 in the control group, which was statistically significant (P =0.036). No significant difference was observed between the two groups in the sleep quality score (P-value = 0.43). Using Melatonin can be a reliable way to treat pain for which there is no standard treatment to date. Although evidence suggests an association between sleep disorders and BMS, melatonin was not superior to a placebo in reducing BMS-induced burning in the present study. Identification of stressors and the ways to struggle with them, further studies with larger samples and higher oral doses, extended follow-up periods and control of psychological factors, and measurement of body mass index that may affect pharmacokinetics are recommended.

Effects of melatonin on both testicular regeneration and recovery of spermatogenesis in busulfan-treated rats

Abstract Testicular damage is one of the most hazardous effects of chemotherapy as it is frequently associated with oligozoospermia and azoospermia. This study aimed at evaluating the protective effect of melatonin in a rat model of busulfan-induced testicular injury. Rats were divided into four groups: control, melatonin, busulfan, busulfan plus melatonin. After 15 days, the semen was collected from the epididymis and testes were assessed. Sperm removed from cauda epididymis and analyzed for sperm count and viability. Testis tissues were also removed, fixed in formalin and were embedded in paraffin. Sections of testis tissue were stained with hematoxylin-eosin for histological examination and prepared for TUNEL (Terminal deoxynucleotide transferase dUTP Nick End Labeling) assay to detect apoptosis and PCNA (proliferating cell nuclear antigenassay) to detect proliferation cells. Serum and testes supernatants were separated to detect testosteron level and oxidative stress parameters. In histological examination, degenerative changes in seminiferous tubules were observed in the experimental groups. In biochemical examination, the total oxidant status (TOS) levels in Busulfan group were significantly higher than in the control group while the total antioxidant status (TAS) levels of all the groups were similar. In conclusion, the beneficial properties of melatonin treatment by its potent anti-oxidants may reduce adverse effects of chemotherapy in the reproductive system in a rodent system.

Involvement of MT2 receptors in protective effects of melatonin against cisplatin-induced gastrointestinal damage in mice

Abstract Melatonin (MLT) reportedly reduces side effects associated with certain antineoplastic agents. Accordingly, we investigated the effect of MLT on cisplatin (CP)-induced gastric emptying (GE) delay. Mice were intraperitoneally pretreated with vehicle (ethanol 5%; control group), MLT (5, 10, or 20 mg/kg), or N-acetylcysteine (NAC; 150 mg/kg), followed by CP treatment (5 mg/kg). Pharmacological modulation was analyzed using relevant receptor antagonists (luzindole: non-selective MT1/MT2 antagonist; 5 mg/kg or 4-P-PDOT: selective MT2 antagonist; 4 mg/kg) before treatment with MLT plus CP. All treatments were performed once daily for three days. GE was assessed using phenol red. Gut morphology was examined using scanning electron microscopy and optical microscopy. Compared with the control, CP decreased GE. Pretreatment with NAC and MLT (5 and 10 mg/kg) did not prevent CP-induced gastric dysmotility; however, pretreatment with 20 mg/kg MLT prevented this effect. In addition, luzindole and 4-P-PDOT suppressed MLT-mediated gastroprotection against cytotoxic effects of CP. CP caused degeneration of the gut mucosa, which was attenuated by MLT treatment. Thus, 20 mg/kg MLT prevented the GE delay and decreased CP-induced adverse effects on the gut mucosa. In addition, the gastroprotective activity was mediated via the MT2 receptor.

The effect of melatonin on in vitro maturation fertilization and early embryo development of mouse oocytes and expression of HMGB1 gene in blastocysts

Antioxidants are commonly used for maturation, fertilization and early development of embryos. Melatonin as an antioxidant have been recently proven to be useful for the assisted reproductive technology. In the present study, we evaluated the roles of melatonin in the in vitro maturation, fertilization, development and also the gene expression of high mobility group box-1 (HMGB1) in the blastocysts. The immature oocytes of BDF1 mice were transferred to the media containing different doses of melatonin (10-6, 10-9, 10-12 M). The blastocysts that developed under in vitro fertilization from each group were stained to determine the cell number of embryos and analyzed to determine the expression level of HMGB1 by real-time PCR. The most effective doses of melatonin for maturation of oocytes were 10-6 and 10-12M (P<0.05). Fertilization rate, early development and the cell number of blastocysts were significantly higher in the group that treated with 10-12 M of melatonin comparing to the other groups. The HMGB1 expression decreased in groups that treated with 10-6M and 10-9M of melatonin and increased in the group that treated with 10-12 M of melatonin, but did not show a significant difference (p˃0.05). From the results, it may be concluded that the melatonin could be effective when the embryos undergo maturation, fertilization and early developmental processes. The HMGB1 expression, as a marker of early development in mice embryos, increased in the groups that treated with low doses of melatonin

La melatonina y su rol en los procesos inflamatorios / Melatonin and its role in inflammatory processes

La melatonina es una hormona neuroendocrina pleiotrópica, producida principalmente por la glándula pineal que regula el ritmo circadiano, es antiinflamatoria, inmunomoduladora, neuroprotectora, antioxidante. Se realizó una revisión sobre el tema empleando artículos de libre acceso en la base de datos Pubmed en el período de enero del 2013 a septiembre del 2018 con el objetivo de describir el rol de esta biomolécula en algunas enfermedades autoinmunes y reumatológicas, así como en otros procesos inflamatorios agudos y crónicos. La melatonina ha demostrado acciones favorables cuando se administra en enfermedades como la esclerosis múltiple, diabetes mellitus tipo l, cáncer. No obstante, puede empeorar las crisis en la artritis reumatoide(AU)

Melatonin is a pleiotropic neuroendocrine hormone, produced mainly by the pineal gland that regulates the circadian rhythm, is anti-inflammatory, immunomodulatory, neuroprotective, antioxidant. A review on the subject was performed using articles of free access in the Pubmed database from January 2013 to September 2018 with the aim of describing the role of this biomolecule in some autoimmune and rheumatological diseases, as well as in other acute and chronic inflammatory processes. Melatonin has shown favorable actions when it is administered in diseases such as multiple sclerosis, diabetes mellitus type I, cancer. However, it can worsen crises in rheumatoid arthritis(AU)

Prophylaxis with melatonin for primary stabbing headache in pediatrics: a case report / Profilaxis con melatonina para cefalea punzante primaria en pediatría: reporte de caso

Abstract Introduction: Primary stabbing headache (or "ice pick headache") is an alteration characterized by brief jabs (short stabs of pain, lasting ~3 seconds), which appear spontaneously, irregularly, and affecting unilaterally or bilaterally. Indomethacin has traditionally been used as the main therapeutic option. However, this drug is ineffective in a considerable percentage of patients and can generate multiple adverse effects that occur at therapeutic doses. Clinical case: A 7-year-old male patient with primary stabbing headache of mild to moderate intensity, lasting 3 to 4 seconds, without relevant history, with normal neurodevelopment, neurological examination and neuroimaging; no triggers were identified. It was started therapeutic trial with Coenzyme Q10; however, no improvement in the symptoms was identified. Treatment and outcomes: A therapeutic management was carried out with Melatonin, which led to complete remission of the symptoms; without adverse effects in the posterior follow-up months. Clinical and scientific relevance: There is little information regarding effective and safe treatments for primary stabbing headache in children. The present case identifies Melatonin as an innovative, effective and safe therapeutic alternative in the treatment of primary stabbing headache in children. This is a significant advance in the understanding of primary stabbing headache in the pediatric population. Conclusion: Melatonin may be an effective and safe therapeutic option for the treatment of primary stabbing headache in pediatric patients. It is necessary to deepen its research, in order to establish its use in a clinical practice guide.

Resumen Introducción: La cefalea punzante primaria, es una alteración que se caracteriza por punzadas breves (∼3 segundos), que aparecen espontáneamente, de forma irregular y afectación unilateral o bilateral. Tradicionalmente se ha utilizado Indometacina como opción terapéutica principal. Sin embargo, este medicamento es inefectivo en un porcentaje considerable de pacientes y puede generar múltiples efectos adversos que se presentan a dosis terapéuticas. Caso clínico: Paciente masculino de 7 años de edad con cefalea punzante primaria de intensidad leve a moderada con una duración entre 3 y 4 segundos sin antecedentes relevantes, con neurodesarrollo, examen neurológico y de neuroimagen normales; no se identificaron desencadenantes. Se inició prueba terapéutica con Coenzima Q10, sin embargo no se identificó mejoría en los síntomas. Tratamiento y resultados: Se realizó un manejo terapéutico con Melatonina que conllevó a remisión completa de la sintomatología y sin efectos adversos en los meses posteriores de seguimiento. Relevancia clínica y científica: Existe poca información respecto a tratamientos efectivos y seguros para cefalea punzante primaria en niños. El presente caso identifica la Melatonina como una alternativa terapéutica innovadora, efectiva y segura en el tratamiento de la cefalea punzante primaria en niños. Lo anterior constituye un avance significativo en la comprensión de la cefalea punzante primaria en la población pediátrica. Conclusión: La melatonina puede ser una opción terapéutica efectiva y segura para el tratamiento de la cefalea punzante primaria en pacientes pediátricos. Se requiere ahondar en su investigación para establecer su uso en una guía de práctica clínica.

Melatonin in perioperative medicine: current perspective

Melatonin, a new addition to the armamentarium of anesthesiologist, has some unique properties that are highly desirable in routine peri-operative care. Available clinical data show that preoperative melatonin is as effective as benzodiazepines in reducing preoperative anxiety with minimal action on psychomotor performance and sleep wake cycle. It may be considered as a safe and effective alternative of benzodiazepines as preoperative anxiolytic. It may have opioid sparing effect, may reduce intraocular pressure, and have role in prevention of postoperative delirium. The short-term administration of melatonin is free from significant adverse effects also

Morphometric evaluation of seminiferous tubules in aged mice testes after melatonin administration

Melatonin, the pineal gland hormone as a direct or indirect antioxidant and free radical scavenger, is involved in the process of both aging and age-related diseases. This study investigates the effects of melatonin on the histology of testicular seminiferous tubules in aged mice. Twenty male, white mice, aged 16 months, that weighed 20-23 gr were equally divided into control and experimental groups. The experimental group was intraperitoneally injected with a daily single dose of 10 mg/kg melatonin for 14 days. The control group received only saline. Six days after the last injection, all mice were sacrificed and the testes were excised and processed for light microscope observation. In the morphometric study, we evaluated testicular seminiferous tubule parameters such as height of germinal epithelium, seminiferous tubule diameter, thickness of interstitial connective tissue and spermatogenesis index [SI]. SPSS software and student's t-test analyzed all parameters to assess the significance of changes between control and experimental groups. Melatonin-treated mice had seminiferous tubules with a wide lumen lined by low height germinal epithelium. The interstitial connective tissue thickened significantly in the experimental group [p<0.05], tubular diameter and germinal epithelium height decreased significantly [p<0.01], and the SI reduced compared to the control group [p<0.001]. The results of this study showed the disadvantages of melatonin on seminiferous tubules of aged mice testes

Efeitos da melatonina sobre as alteraçöes do perfil lipídico e glicêmico em ratas expostas à luz contínua / Effects of melatonin on the alterations of the glicemic and lipidic profiles in rats exposed to continuous light

A melatonina, (MLT) um hormônio produzido pela pineal, em sua síntese obedecida por ritmo circadiano que é coordenado pelo sistema retino-hipotálamo-pineal, sendo ativado pela escuridäo. Estudos recentes relacionam a pinealectomia cirúrgica à induçäo de estado pré-diabético e simulaçäo de síndrome dos ovários policísticos. Aferir alteraçöes no perfil bioquímico do colesterol, triglicérides, glicose e progesterona em ratas expostas à luz contínua (LC). Foram utilizadas 42 ratas mantidas em gaiolas individuais e divididas em 3 grupos. Grupo de Estudo - GE (n=22) animais expostos a LC por 8 meses. No 4§ mês realizou-se Ooforectomia à direita e iniciou-se a administraçäo de MLT (200 mg IM) diariamente por 4 meses. Grupo controle I - (GCI) (n=10) animais expostos à LC por 8 meses. Grupo Controle II - GCII (n=10) animais expostos a LC por 8 meses, no 4§ mês realizou-se Ooforectomia à direita e administrou-se etanol por 4 meses. Ao final do experimento foi realizada Ooforectomia à esquerda nos 3 grupos. Coletou-se 1 ml de sangue no início, no 4§ e 8§ mês de experimento para dosagem bioquímica. A análise estatística foi realizada segundo a análise de variância por postos de Friedmann e teste de Mann Whitney. Näo observou-se relaçäo ou variaçäo entre os valores bioquímicos estudados. Os valores de progesterona sugeriram a presença de estado anovulatório crônico nos animais estudados. Em ratas, os níveis de glicemia, colesterol e triglicérides näo se alteraram frente à pinealectomia física. Estes resultados podem ter sofrido forte influência pelo estresse induzido pela luz. Outros estudos precisam confirmar a associaçäo de melatonina, diabete mellitus e síndrome dos ovários policísticos

La melatonina: una revisión de su farmacología / Melotonin: review of pharmacology

La melatonina es una hormona de la glándula pineal, cuya secreción está bajo la influencia del ciclo de luz-oscuridad. Su mayor concentración, en plasma, se encuentra durante la noche, por lo qu se cree que juega un papel en la regulación del sueño. en dosis farmacológicas, puede actuar como facilitador del sueño e hipnótico. Además, algunos estudios muestran que podría tener un papel en el tratamiento de la sintomatología del "jet lag". Sus efectos antigonadales, aunque aún controversiales, podrían ser importantes en algunas patologías.

Melatonina / Melatonin

Se revisan las principales acciones fisiológicas de la melatonina, destacando sus efectos metabólicos y endocrinológicos y sus influencias sobre el sistema nervioso y el inmunológico. Se señalan los factores que estimulan la secreción de la melatonina en la glándula pineal. Entre ellos destaca la oscuridad, por lo que la melatonina ha sido considerada como el mensajero de la noche y la reguladora de los ritmos circadianos. Se señalan igualmente los posibles usos terapéuticos de la melatonina, de los cuales el más importante hasta ahora es la regulación del ciclo vigilia-sueño y la prevención del jet-lag. Por el momento se discuten sus eventuales proyecciones terapéuticas derivadas de efectos antioxidantes; inmunomoduladores y cardioprotectores. Los efectos laterales indeseables son muy escasos con la dosis habituales de 3 a 10 mg

La melatonina en el sistema inmunoneuroendocrino / Melatonin in the immuno-neuro-endocrine system

El conocimiento actual de las relaciones neuroendocrinas e inmunológicas confiere un rol importante a la melatonina (MT) en la regulación de los ritmos circadianos de los mamíferos. La función de la glándulapinela en todas las especies es traducir información del ciclo luz/oscuridad a los ritmos fisiológicos del organismo. La MT es producida casi exclusivamente en la oscuridad. En los humanos la secreción ocurre en correspondencia a la edad, disminuyendo en la vejez; guarda relación inversa con la temperatura del cuerpo; evidencia un efecto anti-estrés, posiblemente a través del sistema opioide; favorece la respuesta inmunológica y protege frente al daño tisular que provocan los radicales libres, por su fuerte acción antioxidante. La MT ha sido usada con éxito en la inducción del sueño en personas que ven perturbado su ritmo habitual de sueño por trabajos nocturnos, el síndrome de jet-lag u otras causas. No se ha logrado beneficio en el tratamiento de trastornos mayores del sueño, ni en la depresión ni en otros trastornos psiquiátricos. La presencia de receptores para la MT en múltiples órganos y sistemas estimula actualmente la investigación clínica sobre estas funciones posibles de la melatonina